NVO

#5064
Novo-Nordisk A/S
37.46
+0.16%
Sector:
Base:
Profit Currency:
Daily Range
37.35
37.54
Year Range
37.33
91.90
Daily Change
+0.16%
Monthly Change
-39.03%
6 month change
-33.96%
Year Change
-58.29%
Previous Close
37.40
Open
37.38
Bid
Ask
Low
37.35
High
37.54
Volume
7 381
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
  • Market Capitalization N/A
  • Employee 70 K
  • Founded N/A
  • CEO Maziar Mike Doustdar
  • Website www.novonordisk.com
  • Headquarter Denmark
  • FIGI BBG000BQBKR3
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
—
Price to sales ratio
—
Dividends per share
—
Dividend yield %
—

Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark.

News